US IPO proceeds reached approximately $115.6 billion through the first half of 2026, a dramatic increase over the prior year, according to Fortune reporting published July 11 -- but the underlying composition of that number tells a more concentrated story than the headline figure suggests. Much of the volume came from a handful of mega-deals, most notably SpaceX's $75 billion Nasdaq debut and SK Hynix's $26.5 billion listing, rather than broad-based issuance spread evenly across sectors.
Strategists interviewed for the piece describe the second half of 2026 as shaping up as a genuine rebalancing rather than a continuation of the same AI-and-chip-dominated pattern. Mid-cap and previously overlooked sectors -- advanced manufacturing, defense and energy specifically -- are preparing to test investor appetite as capital increasingly looks beyond the small handful of crowded mega-cap AI and chip trades that dominated the first half.
The broadening thesis rests on several converging trends happening simultaneously: AI adoption is accelerating across industrial markets rather than staying contained to pure-play AI companies, defense spending continues rising amid ongoing geopolitical tension, and private capital keeps funding category-leading companies at high valuations across sectors well beyond AI -- creating a deep pipeline of well-capitalized, later-stage private companies that could credibly go public once market conditions stay favorable.
“The test for the back half of 2026 is already underway in real time.”
Investors, per the reporting, are increasingly willing to back growth tied to automation, software and smart manufacturing, favoring businesses with clearer earnings visibility and infrastructure-like cash flows over the more speculative, pre-revenue profiles that characterized some of the AI mega-IPOs. That's a meaningful shift in risk appetite: rather than chasing the biggest, most AI-native name available, public-market investors are showing renewed willingness to underwrite more conventional, cash-generative businesses in adjacent categories.
The test for the back half of 2026 is already underway in real time. Holtec Nuclear Corp filed for a Nasdaq listing this same week, betting on nuclear energy's role in powering AI data centers. Apnimed filed for its IPO on the strength of a late-stage sleep-apnea drug candidate, part of a broader reopening of the biotech IPO window. Corvex's AI-infrastructure reverse merger through a public shell offers a different, faster path to public markets entirely. Each represents a distinct test of whether investor appetite genuinely extends beyond the AI mega-cap trade or whether 2026's IPO boom remains concentrated in a handful of headline-grabbing names.
For founders weighing IPO timing, the reported broadening is a signal that public-market windows may be opening for well-positioned companies outside pure AI plays specifically, provided they can show the earnings visibility and infrastructure-like cash flows investors are reportedly favoring. For LPs and growth investors, a genuinely broadening IPO market would mark a healthier, more durable form of market recovery than one dependent entirely on a handful of mega-cap AI names continuing to perform.
The bear case: IPO market broadening claims have circulated before in past cycles without fully materializing, and any broader market volatility or AI-sector correction could just as easily concentrate investor attention back onto the safest, most liquid mega-cap names rather than spreading capital toward smaller, less-proven issuers. What to watch next: how Holtec Nuclear, Apnimed and the current wave of smaller IPO filings actually price and trade relative to their initial ranges, which will be the real test of whether the broadening thesis holds.